Altered P-glycoprotein expression in AIDS patients with HIV encephalitis

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 10, 2004, Pages 1038-1047

  Langford, Dianne ^a   Grigorian, Aline ^a   Hurford, Rosemary ^b   Adame, Anthony ^b   Ellis, Ronald J ^b   Hansen, Lawrence ^a,b   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Highly active anti retroviral therapy (HAART); HIV; MDR 1; Neurodegeneration; P glycoprotein

Indexed keywords

CD31 ANTIGEN; CD45 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEIN P; MICROTUBULE ASSOCIATED PROTEIN 2; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ASTROCYTE; AUTOPSY; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENCEPHALITIS; ENDOTHELIUM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ENCEPHALITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOREACTIVITY; MACROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 5644300853     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.10.1038     Document Type: Article

References (61)

1. Masliah E, Achim C, Ge N, Wiley C. Cellular neuropathology in HIV encephalitis. J Neurol Sci 1992;113:28
2. Masliah E, Ge N, Achim C, DeTeresa R, Wiley C. Patterns of neurodegeneration in HIV encephalitis. NeuroAIDS 1996;1:161-73
3. Budka H. Neuropathology of human immunodeficiency virus infection. Brain Pathol 1991;1:163-75
4. Langford D, Masliah E. Crosstalk between components of the blood-brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol 2001;11:306-12
5. Dallasta L, Pisarov L, Esplen J, et al. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999;155:1915-27
6. Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002;16:1019-29
7. Vago L, Bonetto S, Nebuloni M, et al. Pathological findings in the central nervous system of AIDS patients on assumed antiretroviral therapeutic regimens: Retrospective study of 1597 autopsies. AIDS 2002;16:1925-28
8. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31:171-77
9. Deutsch R, Ellis RJ, McCutchan JA, Marcotte TD, Letendre S, Grant I. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS 2001; 15:1898-99
10. Power C, Gill MJ, Johnson RT. Progress in clinical neurosciences: The neuropathogenesis of HIV infection: Host-virus interaction and the impact of therapy. Can J Neurol Sci 2002;29:19-32
11. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999;13:1249-53
12. Grant I, Heaton R, Atkinson J, Group H. Neurocognitive disorder in HIV-1 infection. In: Oldstone M, Vitovic L, eds. Current topics in microbiology and immunology. HIV and dementia. 1st Ed. Heidelberg: Springer-Verlag, 1995: 9-30
13. McArthur J, Hoover D, Bacellar H, et al. Dementia in AIDS patients: Incidence and risk factors. Neurology 1993;43:2245-52
14. Starace F, Dijkgraaf M, Houweling H, Postma M, Tramarin A. HIV-associated dementia: Clinical, epidemiological and resource utilization issues. AIDS Care 1998;10(Suppl 2):S113-S121
15. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94
16. Jones K, Bray PG, Khoo SH, et al. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance? AIDS 2001;15:1353-58
17. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-42
18. Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999;16:1206-12
19. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28: 655-60
20. Gupta S, Gollapudi S. P-glycoprotein (MDR 1 gene product) in cells of the immune system: Its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993;13:289-301
21. Felix RA, Barrand MA. P-glycoprotein expression in rat brain endothelial cells: Evidence for regulation by transient oxidative stress. J Neurochem 2002;80:64-72
22. Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 1999;126:509-16
23. Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002;277:38915-20
24. Heaton R, Grant I, Butters N, et al. The HNRC 500-neuropsychology of HIV infection at different disease stages. J Int Neuropsych Soc 1995;1:231-51
25. Masliah E, Achim C, Ge N, DeTeresa R, Terry R, Wiley C. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 1992;32:321-29
26. Sanders V, Everall IP, Johnson RW, Masliah E. Fibroblast growth factor modulates HIV co-receptor expression by neural cells. HNRC Group. J Neurosci Res 2000;59:671-79
27. Toth K, Vaughan MM, Slocum HK, et al. New immunohistochemical "sandwich" staining method for MDR1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol 1994;144:227-36
28. Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 1997;42:963-72
29. Everall IP, Trillo-Pazos G, Bell C, Mallory M, Sanders V, Masliah E. Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: A strategy for neuroprotection. J Neuropathol Exp Neurol 2001;60:293-301
30. Pardridge WM, Golden PL, Kang YS, Bickel U. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 1997;68:1278-85
31. Gaillard PJ, van der Sandt IC, Voorwinden LH, et al. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res 2000;17:1198-205
32. Schinkel AH. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol 2001;500:365-72
33. Seetharaman S, Barrand MA, Maskell L, Scheper RJ. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 1998; 70:1151-59
34. Meaden ER, Hoggard PG, Maher B, Khoo SH, Back DJ. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1329-32
35. Tan KH, Purcell WM, Heales SJ, McLeod JD, Hurst RD. Evaluation of the role of P-glycoprotein in inflammation induced blood-brain barrier damage. Neuroreport 2002;13:2593-97
36. Tulpule A, Sherrod A, Dharmapala D, et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res 2002; 26:121-27
37. Andreana A, Gollapudi S, Kim CH, Gupta S. Salmonella typhimurium activates human immunodeficiency virus type 1 in chronically infected promonocytic cells by inducing tumor necrosis factor-alpha production. Biochem Biophys Res Commun 1994;201: 16-23
38. Andreana A, Gollapudi S, Gupta S. Salmonella typhimurium induces expression of P glycoprotein (multidrug resistance 1 gene product) in a promonocytic cell line chronically infected with human immunodeficiency virus type 1. J Infect Dis 1994;169:760-65
39. Nuti SL, Mehdi A, Rao US. Activation of the human P-glycoprotein ATPase by trypsin. Biochemistry 2000;39:3424-32
40. Nuti SL, Rao US. Proteolytic cleavage of the linker region of the human P-glycoprotein modulates its ATPase function. J Biol Chem 2002;277:29417-23
41. Doi AM, Holmes E, Kleinow KM. P-glycoprotein in the catfish intestine: Inducibility by xenobiotics and functional properties. Aquat Toxicol 2001;55:157-70
42. Budka H, Wiley C, Kleihues P, et al. HIV-associated disease of the nervous system: Review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1991;1:143-52
43. Langford T, Letendre SL, Larrea GJ, Masliah E. Changing Patterns in the Neuropathogenesis of HIV During the HAART Era. Brain Pathol 2002;11:306-12
44. van der Sandt IC, Gaillard PJ, Voorwinden HH, de Boer AG, Breimer DD. P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharm Res 2001;18:587-92
45. Fiala M, Liu QN, Sayre J, et al. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest 2002;32:360-71
46. Bussolino F, Mitola S, Serini G, Barillari G, Ensoli B. Interactions between endothelial cells and HIV-1. Int J Biochem Cell Biol 2001; 33:371-90
47. Kanmogne GD, Kennedy RC, Grammas P. HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: Possible pathway for HIV entry into the brain and HIV-associated dementia. J Neuropathol Exp Neurol 2002;61:992-1000
48. Persidsky Y, Zheng J, Miller D, Gendelman HE. Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia. J Leukoc Biol 2000;68: 413-22
49. Nottet H. Interactions between macrophages and brain microvascular endothelial cells: Role in pathogenesis of HIV-1 infection and blood-brain barrier function. J Neurovirol 1999;5:659-69
50. Haughey NJ, Mattson MP. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr 2002;31(Suppl 2):S55-S61
51. Romero-Alvira D, Roche E. The keys of oxidative stress in acquired immune deficiency syndrome apoptosis. Med Hypotheses 1998;51:169-73
52. Viviani B, Corsini E, Binaglia M, Galli CL, Marinovich M. Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience 2001;107:51-58
53. Kondo T, Kinouchi H, Kawase M, Yoshimoto T. Differential response in the release of hydrogen peroxide between astroglial cells and endothelial cells following hypoxia/reoxygenation. Neurosci Lett 1996;215:103-6
54. Speck RR, Yu XF, Hildreth J, Flexner C. Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis 2002;186:332-40
55. Raviv Y, Puri A, Blumenthal R. P-glycoprotein-overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane. Faseb J 2000;14:511-15
56. Lee CG, Ramachandra M, Jeang KT, Martin MA, Pastan I, Gottesman MM. Effect of ABC transporters on HIV-1 infection: Inhibition of virus production by the MDR1 transporter. Faseb J 2000;14:516-22
57. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 2001;17:1009-19
58. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001;59:806-13
59. Lanier ER, Sturge G, McClernon D, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS 2001;15: 747-51
60. Lambotte O, Deiva K, Tardieu M. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol 2003;13:95-103
61. Irlbeck D, Stanhope MJ, Douady C, et al. Phylogenetic analyses of HIV-I from an AIDS dementia patient suggest compartmentalized evolution in the mid-frontal gyrus of the brain. From the XI International Workshop on Drug Resistance and Treatment Strategies, held in Seville, Spain, 2002